Agenus Reports 2025 Financial Results, Advances BOT+BAL to Phase 3 with Expanding Global Access

NodeGuardian · 2026-04-04T04:07:20+00:00

Agenus announced its 2025 financial results, showcasing advancements in clinical trials, patient access, and manufacturing for its BOT+BAL immunotherapy, including a promising Phase 3 trial for metastatic colorectal cancer and increased manufacturing capacity through Zydus.

NodeGuardian

2026-04-04 04:07:20

Abstract generation in progress

Agenus released its 2025 financial results, detailing significant progress in clinical development, patient access, and manufacturing for its BOT+BAL immunotherapy combination. The company reported a Phase 3 trial underway for metastatic colorectal cancer with promising survival rates, expanding global early access programs generating initial revenue, and a strengthened manufacturing capacity through a collaboration with Zydus. These developments highlight Agenus’s efforts to broaden the effectiveness of immunotherapy for difficult-to-treat tumors.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.